Merck & Co., Inc. has agreed to pay $10.8bn for Prometheus Biosciences, Inc. and its Phase III-ready TNF-like ligand 1A (TL1A) inhibitor PRA023, which showed promising efficacy in inflammatory bowel disease (IBD) indications late last year. The deal gives Merck a potential blockbuster immunology asset that may help it make up for some of the revenue it will lose at the end of this decade after its top-selling product Keytruda (pembrolizumab) loses exclusivity.
Analysts cheered the deal, announced 16 April, despite the high price tag, as a means of diversifying the big pharma’s portfolio beyond Keytruda specifically and oncology generally
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
